CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Open access
Hirschfield, Gideon M, Bowlus, Christopher L, Jones, David E J, Kremer, Andreas E, Mayo, Marlyn J, Tanaka, Atsushi, Andreone, Pietro, Jia, Jidong, Jin, Qinglong, Macías-Rodríguez, Ricardo U, Cobitz, Alexander R, Currie, Brooke M, Gorey, Ciara, Lazic, Ivana, Podmore, Danielle, Ribeiro, Andrea, Shannon, Jennifer B, Swift, Brandon, McLaughlin, Megan M, Levy, Cynthia, Abe, Masanori, Adebayo, Danielle, Ampuero Herrojo, Javier, Anders, Maria, Atsukawa, Masanori, Ayoub, Walid, Bessone, Fernando, Bocus, Paolo, Borg, Brian, Cai, Dachuan, Calvaruso, Vincenza, Carlebach, Matthias, Carmiel, Michal, Cejas, Nora, Chakrabarty, Gayatri, Christoph, Sandra, Corless, Lynsey, Corpechot, Christophe, Corrigan, Margaret, Costentin, Charlotte, Crosignani, Andrea Luigi, da Cunha, Simone, Alvares-da-Silva, Mario, Dimitrov, Dimitar, Dreizin, Vera, Etzion, Ohad, Fernandez, Roberto, Gaite, Luis, Galron, Ehud, Gietka, Jan, Gomez Dominguez, Elena, Gordon, Stuart, Gruz, Fernando, Han, Huanqin, Han, Tao, Harman, David, Hejda, Vaclav, Invernizzi, Pietro, Jacobson, Ira, Jalal, Prasun Kumar, Janczewska, Ewa, Janik, Krzysztof, Kagawa, Tatehiro, Kallis, Yiannis, Kappus, Matthew, Kawata, Kazuhito, Kimura, Takefumi, Komori, Atsumasa, Kusano, Fumihiko, Ladron de Guevara-Cetina, Alma Laura, Leroy, Vincent, Lin, Bingliang, Liu, Yanmin, Lleo de Nalda, Ana, Londoño Hurtado, María Carlota, Louvet, Alexandre, Ma, Xiong, Malova, Elena, Manolakopoulos, Spilios, Martinez, Agustin, Mason, Andrew, Mells, George, Mendes, Liliana, Miele, Luca, Morisco, Filomena, Mularczyk, Aldona, Mulcahy, Victoria, Mumtaz, Khalid, Muñoz-Espinosa, Linda, Namisaki, Tadashi, Nikolov, Nikolay, Osipenko, Marina, Pagadala, Mangesh, Patel, Janisha, Patel, Bhaktasharan, Perez, Francisco, Pezzoto, Cesar, Ramage, John, Reddy, Rajender, Rochling, Fedja, Romeiro, Fernando, Safadi, Rifaat, Salcedo Plaza, Magdalena, Sanada, Taku, Sarkar, Monika, Sheridan, David, Simon, Krzysztof, Smakotina, Svetlana, Sperl, Jan, Ständer, Sonja, Takaguchi, Koichi, Tchernev, Konstantin, Thorburn, Douglas, Trebicka, Jonel, Tsuge, Masataka, Tsuji, Keiji, Tsuji, Kunihiko, Vasura, Adam, Verhelst, Xavier, Vetter, Marcel, Villamil, Alejandra, Vinnitskaya, Elena, Weinstein, Debra, Wu, Xiaoping, Yanase, Mikio, Zharkova, Maria, Zhong, Yandan · 2026 · The Lancet Gastroenterology & Hepatology

Abstract

Background Cholestatic pruritus is common and undertreated in primary biliary cholangitis (PBC) and negatively affects patients' lives. We aimed to evaluate the safety and efficacy of linerixibat, an ileal bile acid transporter inhibitor, as a specific antipruritic therapy in patients with PBC. Methods We conducted a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Patients with PBC and moderate-to-severe pruritus (Worst Itch Numerical Rating Scale [WI-NRS] ≥4) were recruited at 115 centres in 19 countries. Patients were randomly assigned to receive either oral linerixibat 40 mg twice a day or a matching placebo through an interactive online response system, with pruritus severity (moderate or severe) and concomitant pruritus treatment (bile acid binding resins, other treatments, or none) as stratification factors. The primary endpoint was change in pruritus over 24 weeks assessed using the WI-NRS, ranging from 0 (no itching) to 10 (worst imaginable itching). Efficacy analyses included all randomly allocated patients; safety analyses included all randomly allocated patients who received one dose of study treatment or more. This study is registered with ClinicalTrials.gov, number NCT04950127. Findings From Dec 1, 2021, to May 13, 2024, a total of 238 patients were randomly assigned to receive either linerixibat (n=119) or placebo (n=119). One (<1%) of 119 patients randomly allocated to receive placebo withdrew before receiving treatment. Patients receiving linerixibat experienced significant improvement in pruritus over 24 weeks compared with placebo (least-squares mean change from baseline -2·86 [95% CI -3·23 to -2·50] for linerixibat vs -2·15 [-2·51 to -1·78] for placebo; adjusted mean difference -0·72 [95% CI -1·15 to -0·28]; p=0·0013). Gastrointestinal adverse events were more frequent in patients treated with linerixibat than with placebo (72 [61%] of 119 vs 21 [18%] of 118 had diarrhoea; 22 [18%] vs four [3%] had abdominal pain). Treatment discontinuations due to gastrointestinal adverse events occurred in eight (7%) of 119 patients in the linerixibat group (of which five were due to diarrhoea) and one (<1%) of 118 in the placebo group. Serious adverse events were reported in 14 (12%) of 119 patients receiving linerixibat and four (3%) of 118 receiving placebo. No deaths were reported during the study. Interpretation Linerixibat significantly improved pruritus versus placebo, supporting its potential to address a major symptom of PBC. An expected increase in diarrhoea in linerixibat-treated patients was observed. Funding GSK.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(25)00192-x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 30 references

Cited by

See all 34

Metadata

Authors
Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., Cobitz, A. R., Currie, B. M., Gorey, C., Lazic, I., Podmore, D., Ribeiro, A., Shannon, J. B., Swift, B., McLaughlin, M. M., Levy, C., Abe, M., Adebayo, D., Ampuero Herrojo, J., Anders, M., Atsukawa, M., Ayoub, W., Bessone, F., Bocus, P., Borg, B., Cai, D., Calvaruso, V., Carlebach, M., Carmiel, M., Cejas, N., Chakrabarty, G., Christoph, S., Corless, L., Corpechot, C., Corrigan, M., Costentin, C., Crosignani, A. L., da Cunha, S., Alvares-da-Silva, M., Dimitrov, D., Dreizin, V., Etzion, O., Fernandez, R., Gaite, L., Galron, E., Gietka, J., Gomez Dominguez, E., Gordon, S., Gruz, F., Han, H., Han, T., Harman, D., Hejda, V., Invernizzi, P., Jacobson, I., Jalal, P. K., Janczewska, E., Janik, K., Kagawa, T., Kallis, Y., Kappus, M., Kawata, K., Kimura, T., Komori, A., Kusano, F., Ladron de Guevara-Cetina, A. L., Leroy, V., Lin, B., Liu, Y., Lleo de Nalda, A., Londoño Hurtado, M. C., Louvet, A., Ma, X., Malova, E., Manolakopoulos, S., Martinez, A., Mason, A., Mells, G., Mendes, L., Miele, L., Morisco, F., Mularczyk, A., Mulcahy, V., Mumtaz, K., Muñoz-Espinosa, L., Namisaki, T., Nikolov, N., Osipenko, M., Pagadala, M., Patel, J., Patel, B., Perez, F., Pezzoto, C., Ramage, J., Reddy, R., Rochling, F., Romeiro, F., Safadi, R., Salcedo Plaza, M., Sanada, T., Sarkar, M., Sheridan, D., Simon, K., Smakotina, S., Sperl, J., Ständer, S., Takaguchi, K., Tchernev, K., Thorburn, D., Trebicka, J., Tsuge, M., Tsuji, K., Tsuji, K., Vasura, A., Verhelst, X., Vetter, M., Villamil, A., Vinnitskaya, E., Weinstein, D., Wu, X., Yanase, M., Zharkova, M., & Zhong, Y.
Affiliations
  • University Health Network (CA)
  • University of California Davis Medical Center (US)
  • NIHR Newcastle Biomedical Research Centre (GB)
  • University of Zurich (CH)
  • The University of Texas Southwestern Medical Center (US)
  • Teikyo University (JP)
  • Capital Medical University (CN)
  • First Hospital of Jilin University (CN)
  • GlaxoSmithKline (United States) (US)
  • GlaxoSmithKline (United Kingdom) (GB)
  • GlaxoSmithKline (Spain) (ES)
  • University of Miami (US)
Corresponding author
Hirschfield, Gideon M
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2026-01
Volume
11
Issue
1
Pages
22-33
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W4415639271
Cited by
34
References
28
Citations by year
2026: 32
FWCI
18.85
Type
journal article
Language
en
Update notices
erratum (2026-04-01)
Open access
Locations
  • The Lancet. Gastroenterology & hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
GlaxoSmithKline (212620/ NCT04950127)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
primary biliary cirrhosis, cholestatic pruritus, antipruritic therapy, bile acid sequestrants, gastrointestinal adverse effects, drug safety, pruritus severity, bile acid metabolism, cholestasis, quality of life, phase 3
MeSH terms
Adult, Aged, Antipruritics, Cholestasis, Double-Blind Method, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Severity of Illness Index, Thiazepines, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2468-1253(25)00192-x
The paper
Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., Cobitz, A. R., Currie, B. M., Gorey, C., Lazic, I., Podmore, D., Ribeiro, A., Shannon, J. B., Swift, B., McLaughlin, M. M., . . . Zhong, Y. (2026). Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(25)00192-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.